| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | -0.025 | 0.4 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | 0.057 | 0.4 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | 0.026 | 0.4 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | selumetinib:vorinostat (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |